Skip to main content
Get Alerts

Data Explorer

Research historical outbreak investigations and the full recall archive, with charts, trends, and advanced filters. Looking for what's happening right now instead? See current Health Alerts.

Recall totals

All FDA and USDA recalls in Public Health Trace, June 2012 to September 2026.

36,949
Total recall recordsAll FDA and USDA recalls in Public Health Trace
9,732
Class I recallsReasonable probability of serious health consequences
24,263
Class II recallsTemporary or medically reversible health consequences
2,873
Class III recallsNot likely to cause adverse health consequences

Quick insights

A snapshot of the most notable patterns across all recorded FDA and USDA recalls.

Most recalled product100 vegetarian Fenugreek Capsules 90 count, 600mg, packaged in 150cc Amber Glass Packer with White Polypropylene Cap. 53 recalls
Most common hazardLack of Assurance of Sterility 2,071 recalls
Newest recallhttp://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/foods-alive-recalls-organic-moringa-leaf-powder-because-possible-health-riskPublished September 4, 2026
Most affected stateHawaii 200 recalls mention this state

Download matching recalls as CSV

CSV exports include up to 5,000 matching rows (applying your current filters), not the full dataset if it's larger.

Filters
Recall details
Location
Date range
Sort results
Clear filters
Metric
View
Recalls announced by month (Year to date)

A chart of recalls grouped by month.

Download CSV

Source: FDA and USDA public dataLast updated

Summary (Year to date)

  • 1,458 recalls have been announced year to date.
  • Aug 2026 was 53% lower than the previous complete period (Jul 2026: 240).
  • The highest complete period was Jun 2026 (297).
  • Sep 2026 is incomplete and not included in the figures above.
  • Complete data
  • Incomplete
Recalls by class

A bar chart of the total number of recalls in this dataset by recall class.

Recalls by class
ClassRecalls
Class II24,263
Class I9,732
Class III2,873
Not Yet Classified1
Download CSV
Recalls by class
ClassRecalls
Class II24,263
Class I9,732
Class III2,873
Not Yet Classified1

Showing 441–460 of 20,406 recalls

FDA Recall United States Terminated 2026 recordClass II

Wellnov Supplements LLC

Product
Liposomal Womens 50+ Liquid Multivitamin Drops. Dosage: 3ml…
Reason
Deviations from current Good Manufacturing Practices (cGMP) that could lead to bacterial pathogen and possible C. Botulinum concerns.
Published
May 27, 2026
Distribution
Nationwide

View recall →

FDA Recall United States Terminated 2026 recordClass II

Wellnov Supplements LLC

Product
Joint Nourish. Dosage:2 tablespoons (30mL). Liquid. For Oral…
Reason
Deviations from current Good Manufacturing Practices (cGMP) that could lead to bacterial pathogen contamination and possible C. Botulinum concerns.
Published
May 27, 2026
Distribution
Nationwide

View recall →

FDA Recall Ongoing 2026 recordClass II

Ascend Laboratories, LLC, Metoprolol Succinate Extended-Release Tablets, USP, 25 mg* Rx Only, Manufactured by: Alkem Laboratories Ltd., India, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-590-01.

by Ascend Laboratories, LLC

Reason
Failed Dissolution Specifications
Published
May 20, 2026
Distribution
Nationwide

View recall →

FDA Recall Ongoing 2026 recordClass II

Buprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx only, Manufactured for: Endo USA, Malvern, PA 19855, NDC 42023-179-05.

by ENDO USA, Inc.

Reason
Crystallization; identified as Buprenorphine free base
Published
May 20, 2026
Distribution
Nationwide

View recall →

FDA Recall Ongoing 2026 recordClass II

Oasis Tears PF, Preservative-Free Lubricant Eye Drops, 10mL/0.34 Fl OZ Bottle, Sterile, Manufactured for: OASIS Medical, Inc., 514 S. Vermont Ave., Glendora, CA 91741, USA, Made in France, NDC 42126-6400-1.

by Oasis Medical, Inc.

Reason
Lack of Assurance of Sterility: The recall is being initiated out of an abundance of caution following FDA observations noted during a recent inspection of Excelvision.
Published
May 20, 2026
Distribution
Nationwide

View recall →

FDA Recall United States Ongoing 2026 recordClass II

Dakota Honey Company

Product
Dakota Honey Company the Honey Flight. 4 Flavors of Spreada…
Reason
Foreign object (stainless steel dust/flakes or shreds of plastic)
Published
May 20, 2026
Distribution
Nationwide

View recall →

FDA Recall United States Ongoing 2026 recordClass II

Dakota Honey Company

Product
Dakota Honey Company Spreadable Spun Honey, Jalapeno. Stir…
Reason
Foreign object (stainless steel dust/flakes or shreds of plastic)
Published
May 20, 2026
Distribution
Nationwide

View recall →

FDA Recall United States Ongoing 2026 recordClass II

Dakota Honey Company

Product
Dakota Honey Company Spreadable Spun Honey, Salted Caramel.…
Reason
Foreign object (stainless steel dust/flakes or shreds of plastic)
Published
May 20, 2026
Distribution
Nationwide

View recall →

FDA Recall United States Ongoing 2026 recordClass II

Dakota Honey Company

Product
Dakota Honey Company Spreadable Spun Honey, Cinnamon-Infused…
Reason
Foreign object (stainless steel dust/flakes or shreds of plastic)
Published
May 20, 2026
Distribution
Nationwide

View recall →

FDA Recall United States Ongoing 2026 recordClass II

Dakota Honey Company

Product
Dakota Honey Company Spreadable Spun Honey, Original. Stir…
Reason
Foreign object (stainless steel dust/flakes or shreds of plastic)
Published
May 20, 2026
Distribution
Nationwide

View recall →

FDA Recall Ongoing 2026 recordClass I

Lactated Ringer's Injection USP, 1000 mL container, Rx only, B. Braun Medical, Inc., Bethlehem, PA 18018-3524 USA, NDC 0264-7750-07.

by B BRAUN MEDICAL INC

Reason
Presence of Particulate Matter.
Published
May 13, 2026
Distribution
Nationwide

View recall →

FDA Recall Ongoing 2026 recordClass II

NAPROXEN ORAL SUSPENSION, USP, 125 mg/5mL, Rx only, 16fl oz (473 mL) bottles, Distributed by: Acella Pharmaceuticals, LLC, Alpharetta, GA 30005, Made in Canada NDC 42192-619-16

by Acella Pharmaceuticals, LLC

Reason
Chemical contamination; presence of lead and lithium above specification
Published
May 13, 2026
Distribution
Nationwide

View recall →

FDA Recall Ongoing 2026 recordClass II

Duloxetine Delayed-Release Capsules USP, 60mg, Rx Only, 90-count bottle, Mfr. by Towa Pharmaceutical Eurpoe S.L., Martorelles, (Barcelona), Spain, Dist. by. Breckenridge Pharmaceutical, Inc., Berkely Heights, NJ 07922, NDC 51991-748-90.

by Breckenridge Pharmaceutical, Inc.

Reason
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
Published
May 13, 2026
Distribution
Nationwide

View recall →

FDA Recall Ongoing 2026 recordClass II

Enalapril Maleate Tablets, USP, 20 mg, 1,000-count bottle, Rx only, Manufactured by: Unique Pharmaceutical Laboratories (A Div. of J.B. Chemicals & Pharmaceuticals Ltd.), Mumbai 400 030, India, Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 64980-688-10.

by JB Chemicals and Pharmaceuticals Ltd

Reason
Failed Impurities/Degradation Specifications:Out of specification result occurred in Organic Impurities Test
Published
May 13, 2026
Distribution
Nationwide

View recall →

FDA Recall Ongoing 2026 recordClass II

Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, In Single-Dose kits containing: 8-mL vial of 30 mg strength, a pre-filled syringe containing 2 mL of diluent, one vial adapter, and one sterile 1¿ 19-gauge safety injection needle, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 69300 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054. NDC Kit Carton: 0480-9262-08; Vial Label: 0480-9260-01; Tray Label: 0480-9262-08; Diluent Label: 0480-9263-21.

by Teva Pharmaceuticals USA, Inc

Reason
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
Published
May 13, 2026
Distribution
Nationwide

View recall →

FDA Recall Ongoing 2026 recordClass II

BD PurPrep, Povidone-iodine 8.3% w/w (0.83% available iodine) with isopropyl alcohol 72.5% w/w Sterile Solution, 0.36 fl. oz. (10.5 mL) x 25 applicators per box. Carefusion 213, LLC, El Paso, TX 79912, subsidary of Becton Dickinson and Co. NDC 54365-014-41

by CareFusion 213, LLC

Reason
Lack of assurance of Sterility: potential product contamination
Published
May 13, 2026
Distribution
Nationwide

View recall →

FDA Recall Ongoing 2026 recordClass II

BD PurPrep, Povidone-iodine 8.3% w/w (0.83% available iodine) with isopropyl alcohol 72.5% w/w Sterile Solution, 25x26mL Applicators per carton. Carefusion 213 LLC, El Paso, TX 79912, NDC 54365-014-42.

by CareFusion 213, LLC

Reason
Lack of assurance of Sterility: potential product contamination
Published
May 13, 2026
Distribution
Nationwide

View recall →

FDA Recall Ongoing 2026 recordClass II

Duloxetine Delayed-Release Capsules, 20 mg, Rx Only, 60 capsules, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807, Made in India, NDC 27241-097-06.

by Ajanta Pharma Ltd.

Reason
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.
Published
May 13, 2026
Distribution
Nationwide

View recall →

FDA Recall Ongoing 2026 recordClass II

Duloxetine Delayed-Release Capsules, 60 mg, Rx Only, 30 capsules, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807, Made in India, NDC 27241-099-03

by Ajanta Pharma Ltd.

Reason
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.
Published
May 13, 2026
Distribution
Nationwide

View recall →

FDA Recall Ongoing 2026 recordClass II

Duloxetine Delayed-Release Capsules, 30 mg, Rx Only, a) 90 Capsules, NDC 27241-098-09, b) 30 capsules, NDC 27241-098-03, c) 1000 Capsules, NDC 27241-098-10, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807, Made in India

by Ajanta Pharma Ltd.

Reason
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.
Published
May 13, 2026
Distribution
Nationwide

View recall →

Data last updated:

Recall records are summarized from official FDA and USDA sources. Notices may be updated, reclassified, terminated, or withdrawn. Always review the linked official notice for the most current instructions. Read the full medical disclaimer.